Cascadian Therapeutics, Inc. (CASC) Is At $4.18 Formed Wedge; I-G Investment Management LTD Lifted By $44.60 Million Its Johnson & Johnson (JNJ) Position

I-G Investment Management Ltd increased Johnson & Johnson (JNJ) stake by 22.45% reported in 2017Q3 SEC filing. I-G Investment Management Ltd acquired 343,053 shares as Johnson & Johnson (JNJ)’s stock rose 6.85%. The I-G Investment Management Ltd holds 1.87 million shares with $243.29M value, up from 1.53 million last quarter. Johnson & Johnson now has $395.38B valuation. The stock increased 0.13% or $0.19 during the last trading session, reaching $147.17. About 600,708 shares traded. Johnson & Johnson (NYSE:JNJ) has risen 12.54% since January 18, 2017 and is uptrending. It has underperformed by 4.16% the S&P500.

Cascadian Therapeutics, Inc. (CASC) formed wedge down with $3.97 target or 5.00% below today’s $4.18 share price. Cascadian Therapeutics, Inc. (CASC) has $211.34 million valuation. The stock decreased 0.95% or $0.04 during the last trading session, reaching $4.18. About 36,110 shares traded. Cascadian Therapeutics, Inc. (NASDAQ:CASC) has declined 30.85% since January 18, 2017 and is downtrending. It has underperformed by 47.55% the S&P500.

Among 23 analysts covering Johnson & Johnson (NYSE:JNJ), 12 have Buy rating, 5 Sell and 6 Hold. Therefore 52% are positive. Johnson & Johnson had 86 analyst reports since August 7, 2015 according to SRatingsIntel. Jefferies maintained the stock with “Hold” rating in Tuesday, September 13 report. Goldman Sachs upgraded Johnson & Johnson (NYSE:JNJ) rating on Monday, March 14. Goldman Sachs has “Neutral” rating and $112 target. The firm has “Buy” rating given on Thursday, August 24 by Cowen & Co. The firm has “Buy” rating given on Wednesday, October 18 by Leerink Swann. The firm has “Equal-Weight” rating given on Wednesday, October 18 by Morgan Stanley. On Friday, July 14 the stock rating was maintained by Jefferies with “Hold”. The rating was upgraded by JP Morgan to “Overweight” on Monday, May 15. The firm earned “Buy” rating on Monday, July 10 by RBC Capital Markets. The company was maintained on Wednesday, April 20 by Barclays Capital. BMO Capital Markets maintained the stock with “Buy” rating in Monday, July 10 report.

I-G Investment Management Ltd decreased Red Hat Inc (NYSE:RHT) stake by 10,100 shares to 14,300 valued at $1.59M in 2017Q3. It also reduced Sun Life Finl Inc (NYSE:SLF) stake by 15,056 shares and now owns 5.50M shares. Salesforce Com Inc (NYSE:CRM) was reduced too.

Investors sentiment is 0.83 in Q3 2017. Its the same as in 2017Q2. It is flat, as 45 investors sold JNJ shares while 871 reduced holdings. only 111 funds opened positions while 645 raised stakes. 1.71 billion shares or 0.90% less from 1.73 billion shares in 2017Q2 were reported. Td Asset Management Inc stated it has 0.61% in Johnson & Johnson (NYSE:JNJ). 11,611 were accumulated by Spc. Royal Retail Bank Of Canada holds 0.74% or 11.90M shares in its portfolio. Hendley & reported 4.26% of its portfolio in Johnson & Johnson (NYSE:JNJ). Lord Abbett Comm Ltd Llc reported 2.24 million shares. Argent Tru invested in 25,903 shares or 1.33% of the stock. Barr E S & Company has invested 3.7% in Johnson & Johnson (NYSE:JNJ). Kelly Lawrence W And Associate Inc Ca accumulated 131,048 shares. Randolph invested 3.57% in Johnson & Johnson (NYSE:JNJ). Commerzbank Aktiengesellschaft Fi reported 0.75% of its portfolio in Johnson & Johnson (NYSE:JNJ). Gm Advisory Grp holds 12,437 shares or 0.49% of its portfolio. Convergence Invest Partners reported 4,596 shares. Assetmark has 225,411 shares for 0.33% of their portfolio. Telos Cap Inc owns 23,287 shares or 1.17% of their US portfolio. Platinum Investment Mgmt invested in 32,800 shares or 0.11% of the stock.

Analysts await Cascadian Therapeutics, Inc. (NASDAQ:CASC) to report earnings on March, 8. They expect $-0.29 earnings per share, up 38.30% or $0.18 from last year’s $-0.47 per share. After $-0.28 actual earnings per share reported by Cascadian Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 3.57% negative EPS growth.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: